MGF Farmácia v. AstraZeneca: Dapagliflozin Patent Appeal Partially Granted
Brazilian compounding pharmacy MGF Farmácia Magistral brought a declaratory judgement action against AstraZeneca AB over BRPI0311323B1, the patent covering the SGLT2 inhibitor dapagliflozin in 5mg and 10mg doses. The Court of Justice of São Paulo partially granted the appeal in a ruling closed on 24 September 2024, leaving the precise scope of the surviving patent claims commercially significant for Brazil’s generic and compounding pharmaceutical sector.
Compounding pharmacy challenges AstraZeneca’s dapagliflozin IP in Brazil
MGF Farmácia Magistral Ltda, a Brazilian compounding pharmacy, initiated declaratory judgement proceedings against AstraZeneca AB at the Court of Justice of São Paulo (Case No. 1102084-87.2022.8.26.0100). The action centred on BRPI0311323B1, AstraZeneca’s granted Brazilian patent covering dapagliflozin — the active ingredient in Farxiga — formulated at 5mg and 10mg doses. Declaratory relief of this type typically seeks a judicial determination that the plaintiff’s activities do not infringe the patent, or that the patent is invalid in whole or in part.
The Court of Justice of São Paulo partially granted the appeal, indicating that the appellate panel found merit in at least some of MGF Farmácia’s arguments but did not accept the full scope of the challenge. A partial grant in declaratory patent proceedings before a Brazilian state appellate court suggests the lower court’s ruling was modified on certain grounds while being upheld on others. The precise contours of what was granted — whether relating to claim invalidity, non-infringement, or procedural matters — are not fully detailed in the available public record.
The case closed on 24 September 2024, though no filing date is recorded in the public docket, making precise duration impossible to calculate. The partial outcome leaves both parties in a nuanced position: AstraZeneca retains some protection under BRPI0311323B1, while MGF Farmácia secured partial relief that may affect its ability to compound or market dapagliflozin formulations. The degree to which this ruling affects Brazil’s broader compounding pharmacy market for SGLT2 inhibitors remains to be seen, particularly as dapagliflozin’s cardiovascular and renal indications have expanded commercial relevance.
Filing to Appeal Granted In Part in 0 days
Case closed 24 September 2024; filing date not on public record
Appeal partially granted: what the São Paulo ruling means for both parties
What ‘appeal granted in part’ means in Brazilian IP proceedings
A partial grant by the Court of Justice of São Paulo means the appellate panel agreed with the appellant (MGF Farmácia) on at least one ground but rejected others. Unlike a full reversal, neither party achieves a clean win. The lower court’s decision is modified — not entirely overturned — meaning some aspects of AstraZeneca’s patent position under BRPI0311323B1 are preserved while others are curtailed or remanded.
Partial appellate reliefMGF Farmácia secures partial relief — but full freedom is not confirmed
A partial grant suggests MGF Farmácia successfully argued at least some of its declaratory claims, which may narrow the enforceability of BRPI0311323B1 against compounding activities. However, because full relief was denied, AstraZeneca retains a surviving patent position. MGF Farmácia’s commercial freedom to compound dapagliflozin in Brazil is likely improved but not unambiguously secured by this ruling alone.
Partial declaratory successAstraZeneca retains partial protection; enforcement scope narrows
AstraZeneca AB did not face a complete invalidation or wholesale non-infringement finding, as the appeal was only partially granted. This preserves some enforceability of BRPI0311323B1 in Brazil. However, the partial reversal likely narrows the scope on which AstraZeneca can rely to exclude compounding pharmacies or generic entrants, potentially requiring reassessment of its Brazilian enforcement strategy for dapagliflozin.
Partial patent survivalBrazilian SGLT2 market faces continued IP uncertainty post-ruling
The partial outcome means neither full market exclusivity nor full generic/compounding freedom is conclusively established for dapagliflozin in Brazil. Compounding pharmacies and potential generic entrants should treat BRPI0311323B1 as a live risk requiring freedom-to-operate analysis. The ruling may also signal that Brazilian courts are willing to scrutinise originator pharmaceutical patents where compounding access is at stake, consistent with Brazil’s broader public health IP jurisprudence.
Ongoing FTO risk in BrazilFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | MGF FARMÁCIA MAGISTRAL LTDA | Individual | Brazilian compounding pharmacy — challenger of BRPI0311323B1 dapagliflozin patentSearch in Eureka ↗ |
| Defendant | AstraZeneca AB | Individual | AstraZeneca AB — originator holder of dapagliflozin patent BRPI0311323B1Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The verdict phrase ‘I grant the appeal in Part’ is characteristic of Brazilian civil appellate decisions where the reviewing judge modifies — rather than fully reverses or affirms — the lower court’s disposition. In declaratory judgement proceedings, a partial grant typically means certain claims or grounds advanced by the appellant were upheld while others failed. The singular judicial voice (‘by my vote’) is consistent with a collegiate panel decision recorded through a reporting judge (relator). The absence of a detailed public disposition means the precise claims affected — whether invalidity, non-infringement, or procedural — cannot be confirmed from the available record alone.
BRPI0311323B1 — Dapagliflozin SGLT2 inhibitor formulation patent
BRPI0311323B1 is a granted Brazilian patent in AstraZeneca AB’s portfolio covering dapagliflozin, a selective SGLT2 (sodium-glucose cotransporter-2) inhibitor. The ‘BRPI’ prefix indicates a national phase entry from a PCT application, with ’03’ suggesting an international filing in 2003, placing its priority in the early-stage SGLT2 inhibitor research era. The patent covers the compound and/or formulations at 5mg and 10mg dosage strengths — the doses commercialised globally as Farxiga/Forxiga — protecting both the active pharmaceutical ingredient and its therapeutic application in Brazil.
BRPI0311323B1 is strategically significant because it anchors AstraZeneca’s market exclusivity for dapagliflozin in Brazil across multiple indications including type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. As one of the first-in-class SGLT2 inhibitors, the patent has attracted challenge from compounding pharmacies seeking to prepare patient-specific formulations. Its partial vulnerability in this case suggests Brazilian courts may be willing to limit originator patent scope where access-to-medicine arguments are raised, a dynamic relevant to all SGLT2 patent holders operating in Brazil.
Should you run an FTO analysis against BRPI0311323B1?
Any Brazilian pharmaceutical company, compounding pharmacy, or generic manufacturer considering the preparation, import, or commercialisation of dapagliflozin formulations at 5mg or 10mg should treat BRPI0311323B1 as a live freedom-to-operate concern. The partial grant in this case suggests some claim limitations may apply, but the surviving claim scope is not publicly nullified. An FTO analysis is essential before entering or expanding in Brazil’s SGLT2 inhibitor market — particularly given dapagliflozin’s broad and growing therapeutic indications.
PatSnap Eureka’s FTO Search Agent can map your product or process against the claims of BRPI0311323B1, identify prior art that informed the partial grant, and surface related AstraZeneca filings in Brazil that may extend protection beyond this single patent. Eureka also monitors Brazilian INPI status changes and related litigation activity, enabling R&D and legal teams to track claim-scope shifts in real time and make evidence-based market-entry decisions.
Run a freedom-to-operate analysis on BRPI0311323B1 to assess your product’s exposure
Run FTO in Eureka →Similar SGLT2 inhibitor patent disputes in Brazilian courts
Cases involving declaratory judgement challenges to pharmaceutical patents before the Court of Justice of São Paulo and Brazilian federal courts, particularly in the SGLT2 inhibitor and diabetes drug classes.
What this case signals for Brazil’s pharmaceutical patent IP landscape
A partial win for a compounding pharmacy against a blockbuster originator patent reflects the tension in Brazilian courts between IP protection and pharmaceutical access.
Brazilian declaratory judgement actions are a credible tool for compounders
MGF Farmácia’s partial success demonstrates that Brazilian compounding pharmacies can use declaratory judgement proceedings to challenge originator patents at the state appellate level. For IP teams monitoring Brazil, this signals that BRPI-series pharmaceutical patents are not immune from challenge — even by smaller market participants. Originator companies should maintain robust claim-by-claim prosecution records.
Dapagliflozin’s expanded indications elevate the commercial stakes of this ruling
Dapagliflozin (Farxiga) has received approvals for type 2 diabetes, heart failure, and chronic kidney disease — making BRPI0311323B1 commercially significant well beyond its original indication. Any narrowing of AstraZeneca’s patent scope in Brazil affects a high-growth therapeutic area. Generic and compounding market participants should monitor downstream claim scope decisions carefully.
LTDA v AstraZeneca — key questions answered
The Court of Justice of São Paulo partially granted MGF Farmácia Magistral’s appeal in a declaratory judgement action concerning AstraZeneca’s BRPI0311323B1 patent covering dapagliflozin 5mg and 10mg. The case closed on 24 September 2024. A partial grant means the lower court decision was modified on at least one ground, but AstraZeneca retains a surviving patent position.
BRPI0311323B1 is AstraZeneca’s granted Brazilian patent covering dapagliflozin, a selective SGLT2 inhibitor commercialised as Farxiga at 5mg and 10mg doses. The ‘BRPI’ designation indicates PCT national phase entry, likely with a 2003 priority date. It is contested because it underpins market exclusivity for a blockbuster drug used in diabetes, heart failure, and kidney disease — making it a target for compounding pharmacies and potential generic entrants in Brazil.
In Brazil, a declaratory judgement action (ação declaratória) allows a party to seek a judicial declaration that its activities do not infringe a patent, or that the patent is invalid. For compounding pharmacies, this is a common mechanism to establish freedom to prepare patient-specific formulations of branded active ingredients. Such actions may be brought before state courts like the Court of Justice of São Paulo alongside or separately from INPI-level invalidity proceedings.
A partial appellate grant indicates that the São Paulo court found merit in some but not all of MGF Farmácia’s arguments. AstraZeneca’s patent BRPI0311323B1 is not fully invalidated or declared non-infringed, so some exclusivity survives. However, the partial ruling may narrow the claims or scope on which AstraZeneca can rely to exclude compounders or generic manufacturers, making a detailed claim-by-claim analysis of the court’s written reasoning essential.
The ruling is specific to BRPI0311323B1 and to the declaratory claims raised by MGF Farmácia in case 1102084-87.2022.8.26.0100. It does not automatically affect other AstraZeneca patents in Brazil. However, the partial grant may signal Brazilian courts’ willingness to limit originator pharmaceutical patent scope in access-sensitive contexts, which is relevant for any party assessing the enforceability of related SGLT2 or diabetes drug patents in the Brazilian market.
PatSnap Eureka searches patents and litigation data to answer instantly.